Gene Page:MAPK7
概括?
| 基因 | 5598 |
| 象征 | MAPK7 |
| Synonyms | BMK1|ERK4|ERK5|PRKM7 |
| Description | mitogen-activated protein kinase 7 |
| Reference | MIM:602521|HGNC:HGNC:6880|Ensembl:ENSG00000166484|HPRD:03952|Vega:OTTHUMG00000059587 |
| Gene type | protein-coding |
| Map location | 17p11.2 |
| Pascal p-value | 1.641E-5 |
| Sherlock p-value | 0.299 |
| eGene | Myers' cis & trans |
| Support | Ascano FMRP targets |
数据源中的基因
| Gene set name | Method of gene set | Description | Info |
|---|---|---|---|
| CV:PGCnp | Genome-wide Association Study | GWAS |
第一节遗传学和表观遗传学注释
eQTL annotation
eQTL annotation| SNP ID | Chromosome | Position | eGene | Gene Entrez ID | pvalue | qvalue | TSS distance | eQTL type |
|---|---|---|---|---|---|---|---|---|
| rs4501739 | chrX | 35960848 | MAPK7 | 5598 | 0.08 | trans |
Section II. Transcriptome annotation
General gene expression (GTEx)
Gene expression of temporal and spatial changes (BrainSpan)
脚注：
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
死神:胎儿(13 - 26 postconception周),ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes the lower 25% and upper 25% of the expression distribution.
Top co-expressed genes in brain regions
| Top 10 positively co-expressed genes | ||
| Gene | Pearson's Correlation | Spearman's Correlation |
| SCGN | 0.72 | 0.37 |
| AC015976.1 | 0.67 | 0.34 |
| PDZRN3 | 0.63 | 0.53 |
| DLX1 | 0.60 | 0.45 |
| myo3a | 0.59 | 0.24 |
| PLS3 | 0.59 | 0.36 |
| AC117395.4 | 0.57 | 0.24 |
| ACADL | 0.57 | 0.54 |
| SP8 | 0.56 | 0.34 |
| AL009178.2 | 0.56 | 0.17 |
| Top 10 negatively co-expressed genes | ||
| Gene | Pearson's Correlation | Spearman's Correlation |
| AF347015.33 | -0.22 | -0.19 |
| MT-CO2 | -0.22 | -0.19 |
| AF347015.27 | -0.22 | -0.18 |
| AF347015.2 | -0.22 | -0.24 |
| MT-CYB | -0.21 | -0.19 |
| AF347015.8 | -0.21 | -0.18 |
| AF347015.31 | -0.21 | -0.17 |
| AF347015.15 | -0.21 | -0.17 |
| AF347015.26 | -0.20 | -0.21 |
| S100A1 | -0.20 | -0.14 |
第四节。蛋白质蛋白相互作用注释
| Interactors | Aliases B | Official full name B | Experimental | 资源 | PubMed ID |
|---|---|---|---|---|---|
| GJA1 | CX43 | DFNB38 | GJAL | ODDD | 间隙连接蛋白，Alpha 1，43KDA | - | HPRD,BioGRID | 12637502 |
| MAP2K5 | HST17454 |MAPKK5 |mek5 |prkmk5 | mitogen-activated protein kinase kinase 5 | ERK5 is phosphorylated by MKK5. | BIND | 12628002 |
| MAP2K5 | HST17454 |MAPKK5 |mek5 |prkmk5 | mitogen-activated protein kinase kinase 5 | - | HPRD,BioGRID | 7759517 |
| MEF2A | ADCAD1 |RSRFC4 |RSRFC9 | myocyte enhancer factor 2A | - | HPRD,BioGRID | 9753748 |
| MEF2C | - | myocyte enhancer factor 2C | - | HPRD,BioGRID | 9753748 |
| MEF2C | - | myocyte enhancer factor 2C | An unspecified isoform of ERK5 phosphorylates MEF2C. This interaction was modeled on a demonstrated interaction between ERK5 from an unspecified species and MEF2C from an unspecified species. | BIND | 12659851 |
| MEF2D | DKFZp686I1536 | myocyte enhancer factor 2D | - | HPRD,BioGRID | 9753748 |
| MYC | bHLHe39 | c-Myc | v-myc myelocytomatosis viral oncogene homolog (avian) | - | HPRD | 9461566 |
| PTPRR | DKFZp781C1038 | EC-PTP | FLJ34328 | MGC131968 | MGC148170 | PCPTP1 | PTP-SL | PTPBR7 | PTPRQ | protein tyrosine phosphatase, receptor type, R | - | HPRD,BioGRID | 12042304 |
| RAF1 | CRAF | NS5 | Raf-1 | c-Raf | v-raf-1 murine leukemia viral oncogene homolog 1 | - | HPRD,BioGRID | 10531364 |
| SGK1 | SGK | 血清/糖皮质激素调节激酶1 | - | HPRD,BioGRID | 11254654 |
| YWHAB | GW128 | HS1 | KCIP-1 | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta polypeptide | - | HPRD,BioGRID | 14679215 |
| YWHAE | 14-3-3E | FLJ45465 | KCIP-1 | MDCR | MDS | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide | 两个杂交 | BioGRID | 14679215 |
V.途径注释
| Pathway name | Pathway size | # SZGR 2.0 genes in pathway | Info |
|---|---|---|---|
| KEGG MAPK SIGNALING PATHWAY | 267 | 205 | 该途径中的所有SZGR 2.0基因 |
| KEGG GAP JUNCTION | 90 | 68 | 该途径中的所有SZGR 2.0基因 |
| KEGG NEUROTROPHIN SIGNALING PATHWAY | 126 | 103 | 该途径中的所有SZGR 2.0基因 |
| KEGG GNRH SIGNALING PATHWAY | 101 | 77 | 该途径中的所有SZGR 2.0基因 |
| BIOCARTA HDAC PATHWAY | 32 | 25 | 该途径中的所有SZGR 2.0基因 |
| BIOCARTA MAPK PATHWAY | 87 | 68 | 该途径中的所有SZGR 2.0基因 |
| BIOCARTA ERK5 PATHWAY | 18 | 15 | 该途径中的所有SZGR 2.0基因 |
| ST GA12 PATHWAY | 23 | 16 | 该途径中的所有SZGR 2.0基因 |
| ST JNK MAPK PATHWAY | 40 | 30 | 该途径中的所有SZGR 2.0基因 |
| PID ERBB1 DOWNSTREAM PATHWAY | 105 | 78 | 该途径中的所有SZGR 2.0基因 |
| PID MAPK TRK PATHWAY | 34 | 31 | 该途径中的所有SZGR 2.0基因 |
| REACTOME SIGNALLING BY NGF | 217 | 167 | 该途径中的所有SZGR 2.0基因 |
| REACTOME TRIF MEDIATED TLR3 SIGNALING | 74 | 54 | 该途径中的所有SZGR 2.0基因 |
| REACTOME NGF SIGNALLING VIA TRKA FROM THE PLASMA MEMBRANE | 137 | 105 | 该途径中的所有SZGR 2.0基因 |
| REACTOME GASTRIN CREB SIGNALLING PATHWAY VIA PKC AND MAPK | 205 | 136 | 该途径中的所有SZGR 2.0基因 |
| REACTOME NUCLEAR EVENTS KINASE AND TRANSCRIPTION FACTOR ACTIVATION | 24 | 20 | 该途径中的所有SZGR 2.0基因 |
| REACTOME ERKS ARE INACTIVATED | 12 | 9 | 该途径中的所有SZGR 2.0基因 |
| Reactome Erk MAPK目标 | 21 | 17 | 该途径中的所有SZGR 2.0基因 |
| REACTOME SIGNALING BY GPCR | 920 | 449 | 该途径中的所有SZGR 2.0基因 |
| REACTOME MAP KINASE ACTIVATION IN TLR CASCADE | 50 | 37 | 该途径中的所有SZGR 2.0基因 |
| REACTOME MAPK TARGETS NUCLEAR EVENTS MEDIATED BY MAP KINASES | 30 | 24 | 该途径中的所有SZGR 2.0基因 |
| REACTOME TRAF6 MEDIATED INDUCTION OF NFKB AND MAP KINASES UPON TLR7 8 OR 9 ACTIVATION | 77 | 57 | 该途径中的所有SZGR 2.0基因 |
| REACTOME NFKB AND MAP KINASES ACTIVATION MEDIATED BY TLR4 SIGNALING REPERTOIRE | 72 | 53 | 该途径中的所有SZGR 2.0基因 |
| REACTOME MYD88 MAL CASCADE INITIATED ON PLASMA MEMBRANE | 83 | 63 | 该途径中的所有SZGR 2.0基因 |
| REACTOME INNATE IMMUNE SYSTEM | 279 | 178 | 该途径中的所有SZGR 2.0基因 |
| REACTOME ACTIVATED TLR4 SIGNALLING | 93 | 69 | 该途径中的所有SZGR 2.0基因 |
| REACTOME IMMUNE SYSTEM | 933 | 616 | 该途径中的所有SZGR 2.0基因 |
| REACTOME TOLL RECEPTOR CASCADES | 118 | 84 | 该途径中的所有SZGR 2.0基因 |
| BERTUCCI MEDULLARY VS DUCTAL BREAST CANCER DN | 169 | 118 | 该途径中的所有SZGR 2.0基因 |
| GAL LEUKEMIC STEM CELL UP | 133 | 78 | 该途径中的所有SZGR 2.0基因 |
| SMIRNOV CIRCULATING ENDOTHELIOCYTES IN CANCER UP | 158 | 103 | 该途径中的所有SZGR 2.0基因 |
| PAX3 FOXO1融合的Ebauer目标 | 207 | 128 | 该途径中的所有SZGR 2.0基因 |
| HUMMERICH SKIN CANCER PROGRESSION DN | 100 | 64 | 该途径中的所有SZGR 2.0基因 |
| LINDGREN BLADDER CANCER CLUSTER 2B | 392 | 251 | 该途径中的所有SZGR 2.0基因 |
| AMUNDSON RESPONSE TO ARSENITE | 217 | 143 | 该途径中的所有SZGR 2.0基因 |
| JAZAG TGFB1 SIGNALING VIA SMAD4 DN | 66 | 38 | 该途径中的所有SZGR 2.0基因 |
| BUYTAERT PHOTODYNAMIC THERAPY STRESS UP | 811 | 508 | 该途径中的所有SZGR 2.0基因 |
| BENPORATH MYC MAX TARGETS | 775 | 494 | 该途径中的所有SZGR 2.0基因 |
| NIKOLSKY BREAST CANCER 17P11 AMPLICON | 10 | 8 | 该途径中的所有SZGR 2.0基因 |
| BYSTRYKH HEMATOPOIESIS STEM CELL QTL TRANS | 882 | 572 | 该途径中的所有SZGR 2.0基因 |
| HOFMANN CELL LYMPHOMA DN | 39 | 29 | 该途径中的所有SZGR 2.0基因 |
| IVANOVA HEMATOPOIESIS LATE PROGENITOR | 544 | 307 | 该途径中的所有SZGR 2.0基因 |
| JIANG HYPOXIA NORMAL | 311 | 205 | 该途径中的所有SZGR 2.0基因 |
| KRASNOSELSKAYA ILF3 TARGETS DN | 46 | 38 | 该途径中的所有SZGR 2.0基因 |
| SANSOM APC MYC TARGETS | 217 | 138 | 该途径中的所有SZGR 2.0基因 |
| SANSOM APC TARGETS REQUIRE MYC | 210 | 123 | 该途径中的所有SZGR 2.0基因 |
| CHEN METABOLIC SYNDROM NETWORK | 1210 | 725 | 该途径中的所有SZGR 2.0基因 |
| DANG BOUND BY MYC | 1103 | 714 | 该途径中的所有SZGR 2.0基因 |
| NOUSHMEHR GBM SOMATIC MUTATED | 9 | 7 | 该途径中的所有SZGR 2.0基因 |
| MARTENS TRETINOIN RESPONSE DN | 841 | 431 | 该途径中的所有SZGR 2.0基因 |
| PURBEY TARGETS OF CTBP1 AND SATB1 DN | 180 | 116 | 该途径中的所有SZGR 2.0基因 |
| KRIEG HYPOXIA NOT VIA KDM3A | 770 | 480 | 该途径中的所有SZGR 2.0基因 |